



21/GAR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Mitchell E. Reff et al.

Group Art Unit: 1644

Application No. 09/019,441

Examiner: M. Jamroz

Filed: February 5, 1998

Title: GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS

* * * * *

REPLY AND AMENDMENT

PURSANT TO 37 C.F.R. §1.116

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

Further to Applicants previous Reply, please amend the above-identified application as follows.

IN THE CLAIMS

Kindly cancel all the current claims and insert the following new claims.

- do not enter
MET
3/29/02
42. A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 1 the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 2, and comprising a human constant region selected from the group consisting of human gamma -1 and human gamma -3 constant regions.
43. The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma -1 constant region.
44. The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma -3 constant region.
45. A pharmaceutical composition containing an anti-human CD23 antibody according to claim 42 and a pharmaceutically acceptable carrier.
46. A pharmaceutical composition containing an anti-human CD23 antibody according to claim 43 and a pharmaceutically acceptable carrier.
- Gr
ant
H2

TECH CENTER 1600/2900

FEB 28 2002

RECEIVED